HomeCompareTNTTF vs ABBV

TNTTF vs ABBV: Dividend Comparison 2026

TNTTF yields 4.18% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $42.9K in total portfolio value
10 years
TNTTF
TNTTF
● Live price
4.18%
Share price
$15.00
Annual div
$0.63
5Y div CAGR
26.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.4K
Annual income
$10,912.61
Full TNTTF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TNTTF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTNTTFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TNTTF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TNTTF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TNTTF
Annual income on $10K today (after 15% tax)
$355.62/yr
After 10yr DRIP, annual income (after tax)
$9,275.72/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $11,780.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TNTTF + ABBV for your $10,000?

TNTTF: 50%ABBV: 50%
100% ABBV50/50100% TNTTF
Portfolio after 10yr
$80.9K
Annual income
$17,842.18/yr
Blended yield
22.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TNTTF
Analyst Ratings
6
Buy
6
Hold
Consensus: Buy
Altman Z
0.6
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TNTTF buys
0
ABBV buys
0
No recent congressional trades found for TNTTF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTNTTFABBV
Forward yield4.18%3.06%
Annual dividend / share$0.63$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR26.6%40.6%
Portfolio after 10y$59.4K$102.3K
Annual income after 10y$10,912.61$24,771.77
Total dividends collected$34.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: TNTTF vs ABBV ($10,000, DRIP)

YearTNTTF PortfolioTNTTF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,230$529.66$11,550$430.00$320.00ABBV
2$12,719$703.74$13,472$627.96$753.00ABBV
3$14,553$943.12$15,906$926.08$1.4KABBV
4$16,848$1,276.73$19,071$1,382.55$2.2KABBV
5$19,777$1,748.86$23,302$2,095.81$3.5KABBV
6$23,590$2,428.85$29,150$3,237.93$5.6KABBV
7$28,669$3,427.86$37,536$5,121.41$8.9KABBV
8$35,605$4,929.01$50,079$8,338.38$14.5KABBV
9$45,340$7,242.80$69,753$14,065.80$24.4KABBV
10$59,426$10,912.61$102,337$24,771.77$42.9KABBV

TNTTF vs ABBV: Complete Analysis 2026

TNTTFStock

The Toronto-Dominion Bank, together with its subsidiaries, provides various financial products and services in Canada, the United States, and internationally. It operates through Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, and Wholesale Banking segments. The company offers personal deposits, such as checking, savings, and investment products; financing, investment, cash management, international trade, and day-to-day banking services to businesses; and financing options to customers at point of sale for automotive and recreational vehicle purchases. It also provides credit cards and payments; real estate secured lending, auto finance, and consumer lending services; point-of-sale payment solutions for large and small businesses; wealth and asset management products, and advice to retail and institutional clients through direct investing, advice-based, and asset management businesses; property and casualty insurance; and life and health insurance products, as well as reinsurance products. The company also provides capital markets, and corporate and investment banking products and services, including underwriting and distribution of new debt and equity issues; advice on strategic acquisitions and divestitures; and trading, funding, and investment services to corporations, governments, and institutions. It offers its products and services under the TD Bank and America's Most Convenient Bank brand names. The company operates through a network of 1,060 branches and 3,401 automated teller machines (ATMs) in Canada, and 1,160 stores and 2,693 ATMs in the United States, as well as offers telephone, digital, and mobile banking services. The Toronto-Dominion Bank was founded in 1855 and is headquartered in Toronto, Canada.

Full TNTTF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TNTTF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TNTTF vs SCHDTNTTF vs JEPITNTTF vs OTNTTF vs KOTNTTF vs MAINTNTTF vs JNJTNTTF vs MRKTNTTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.